Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys Launches Partnership with CellnTec for MRM-MS Assay Development

Premium

Swiss proteomics firm Biognosys has launched a partnership with cell culture company CellnTec to study the proteomics of aging.

Under the partnership, Biognosys has created a custom multiple-reaction monitoring mass spec assay for quantifying proteins linked to aging and screening for anti-aging substances.

The assay quantifies 100 proteins involved in age-related processes. Using it in combination with CellnTec's VitroAge culture medium – which is designed to encourage the natural aging of cultured cells – CellnTec has identified a number of proteins linked to the aging process and aims to develop mechanistic understandings of the anti-aging abilities of various agents.

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.